Werewolf Therapeutics
HOWL
41 hedge funds and large institutions have $107M invested in Werewolf Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
109% more capital invested
Capital invested by funds: $51.1M → $107M (+$55.7M)
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
17% more funds holding
Funds holding: 35 → 41 (+6)
9.48% more ownership
Funds ownership: 66.97% → 76.46% (+9.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.19M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$2.32M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.44M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$832K |
| 5 |
Two Sigma Advisers
New York
|
+$453K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$1.13M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$374K |
| 3 |
Millennium Management
New York
|
-$56.9K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$26.6K |
| 5 |
BlackRock
New York
|
-$12.5K |
HOWL Hedge Fund Activity: Q4 2023 in Review
41 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q4 2023, worth a combined $107M — up 109% from $51.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new HOWL positions and 4 closed out — a net gain of 6 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $5.19M. The largest seller was Laurion Capital Management, cutting an estimated $1.13M.
- 41 institutional investors held Werewolf Therapeutics (HOWL) as of Q4 2023, up from 35 in Q3 2023.
- Funds reported $107M of Werewolf Therapeutics stock for Q4 2023, up 109% quarter-over-quarter.
- 10 funds opened new Werewolf Therapeutics positions in Q4 2023 and 4 closed out, a net change of +6 holders.
- The largest Werewolf Therapeutics buyer in Q4 2023 was Adage Capital Partners, an estimated $5.19M added.
- The largest Werewolf Therapeutics seller in Q4 2023 was Laurion Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q4 2023.